Innovent Biologics Inc 1801-HK:Hong Kong Stock Exchange

*Data is delayed | HKD
Last | 9:13 AM CTT
37.10quote price arrow up+0.40 (+1.09%)
52 week range
18.06 - 82.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close36.70
  • 52 Week High82.00
  • 52 Week High Date11/22/21
  • 52 Week Low18.06
  • 52 Week Low Date05/10/22

Key Stats

  • Market Cap6,808.56M
  • Shares Out1,462.11M
  • 10 Day Average Volume11.62M
  • Dividend-
  • Dividend Yield-
  • Beta0.55
  • YTD % Change-23.94

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close36.70
  • 52 Week High82.00
  • 52 Week High Date11/22/21
  • 52 Week Low18.06
  • 52 Week Low Date05/10/22
  • Market Cap6,808.56M
  • Shares Out1,462.11M
  • 10 Day Average Volume11.62M
  • Dividend-
  • Dividend Yield-
  • Beta0.55
  • YTD % Change-23.94

RATIOS/PROFITABILITY

  • EPS (TTM)-2.64
  • P/E (TTM)-14.04
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Innovent Biologics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The...
De-Chao Yu Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Yong Jun Liu Ph.D.
President
Hao Xi Ede
Chief Financial Officer, Executive Director
Address
168
Dongping Street, Suzhou Industrial Park
Suzhou, JNG
215123
China